AVTX
Avalo Therapeutics, Inc.Company Information
- Company Name
- Avalo Therapeutics, Inc.
- CIK
- CIK0001534120
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AVTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AVTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-11-13
- Last sale
- 2026-06-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 313,465
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 28,701,406
- Shares outstanding
- 20,106,925
- Ownership
- 142.74%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 4.76%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series D Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Series E Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | - | ||||||
| Series C Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | - | ||||||
| Series C1 Preferred Stock | 0 | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
Assets | ||||||||||||||||||
| Inventory Net | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 85 | 25 | 16 | 27 | 42 | 125 | 135 | 82 | 93 | 110 | 7 | 10 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 408 | 89 | 105 | 114 | 115 | 127 | 139 | 86 | 96 | 111 | 8 | 13 | ||||||
| Short Term Investments | 315 | 57 | 82 | 85 | 71 | - | 0 | - | - | - | - | - | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | 1 | 1 | 0 | 0 | 0 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 8 | 7 | 7 | 2 | 2 | 2 | 4 | 3 | 2 | 1 | 1 | 1 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Investments | 72 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Goodwill | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 14 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 491 | 100 | 116 | 125 | 127 | 139 | 151 | 98 | 108 | 124 | 21 | 29 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accounts Payable Current | 3 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 18 | 11 | 13 | 7 | 7 | 5 | 6 | 7 | 8 | 7 | 4 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 21 | 12 | 13 | 8 | 9 | 6 | 7 | 61 | 96 | 216 | 5 | 6 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Asset Acquisition Contingent Consideration Liability Current | - | - | - | - | - | - | - | 5 | 5 | 13 | - | - | ||||||
| Derivative Liabilities Current | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Accrued Royalties Current And Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 19 | 18 | 18 | 23 | 10 | 8 | 8 | 12 | 11 | 6 | 6 | 5 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 42 | 32 | 33 | 34 | 22 | 16 | 18 | 76 | 110 | 225 | 14 | 15 | ||||||
Temporary Equity | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 11 | 11 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 449 | 68 | 83 | 92 | 105 | 123 | 133 | 21 | -14 | -113 | 7 | 15 | ||||||
| Additional Paid In Capital | 954 | 536 | 531 | 526 | 509 | 506 | 503 | 356 | 344 | 344 | 342 | 341 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | -0 | - | 0 | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -505 | -468 | -449 | -435 | -404 | -383 | -370 | -335 | -358 | -456 | -335 | -327 | ||||||
| Liabilities And Stockholders Equity | 491 | 100 | 116 | 125 | 127 | 139 | 151 | 98 | 108 | 124 | 21 | 29 | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 53 | 25 | 19 | 18 | 11 | 11 | 10 | 10 | 1 | 1 | 1 | 192 | ||||||
| Shares Outstanding | 53 | 25 | 19 | 18 | 11 | 11 | 10 | 10 | 1 | 1 | 1 | 192 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | - | - | - | 5 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAvalo Therapeutics, Inc. (AVTX) — SEC Financial Statements & Analysis
Avalo Therapeutics, Inc. (AVTX) is a pharmaceutical preparations company, incorporated in DE. Avalo Therapeutics, Inc. trades on Nasdaq as: AVTX. Avalo Therapeutics, Inc. (AVTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Avalo Therapeutics, Inc. carries a market cap of $805.77M, a P/E ratio of -8.03x, a P/B ratio of 1.80x, a P/S ratio of 13657.05x, an enterprise value of $720.15M, and an EV/EBITDA multiple of -7.89x. On profitability, it posts a gross margin of 33.26%, an operating margin of -154844.07%, a net margin of -170055.93%, a Return on Equity (ROE) of -36.27%, a Return on Assets (ROA) of -32.50%, and a Return on Invested Capital (ROIC) of -42.98%. Per share, it reports EPS of $-2.30, diluted EPS of $-2.30, free cash flow per share of $-1.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -86.62% year-over-year, net income growth of 117.10% year-over-year, and EPS growth of -46.08% year-over-year. On the balance sheet, it maintains a current ratio of 19.31x, a quick ratio of 18.95x, working capital of $386.80M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.09, an interest coverage ratio of -16.11x, free cash flow of $-68.29M (TTM), and net debt of $-85.61M. Figures sourced from SEC EDGAR.
- Market Cap
- $805.77M
- P/E TTM
- -8.03x
- EPS TTM
- $-2.30
- P/B TTM
- 1.80x
- ROE TTM
- -36.27%
- ROA TTM
- -32.50%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-68.29M
- Net Revenue TTM Growth 1Y
- -86.62%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Avalo Therapeutics, Inc. in?
Avalo Therapeutics, Inc. (AVTX) operates in the Pharmaceutical Preparations industry.
What exchange does AVTX trade on?
Avalo Therapeutics, Inc. (AVTX) trades on the Nasdaq.
Where is Avalo Therapeutics, Inc. incorporated?
Avalo Therapeutics, Inc. is incorporated in DE.
When was Avalo Therapeutics, Inc. (AVTX)'s most recent SEC filing?
Avalo Therapeutics, Inc. (AVTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is AVTX's market cap?
Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $805.77M as of 2026-06-30.
What is AVTX's EPS (earnings per share)?
Avalo Therapeutics, Inc. (AVTX)'s trailing twelve month EPS is $-2.30 as of 2026-06-30.
What is AVTX's ROE (return on equity)?
Avalo Therapeutics, Inc. (AVTX)'s trailing twelve month Return on Equity (ROE) is -36.27% as of 2026-06-30.
What is AVTX's ROA (return on assets)?
Avalo Therapeutics, Inc. (AVTX)'s trailing twelve month Return on Assets (ROA) is -32.50% as of 2026-06-30.
What is AVTX's ROIC (return on invested capital)?
Avalo Therapeutics, Inc. (AVTX)'s trailing twelve month Return on Invested Capital (ROIC) is -42.98% as of 2026-06-30.
What is AVTX's EV/EBITDA?
Avalo Therapeutics, Inc. (AVTX)'s trailing twelve month EV/EBITDA is -7.89x as of 2026-06-30.